Literature DB >> 12122208

alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.

C Lo Bianco1, J-L Ridet, B L Schneider, N Deglon, P Aebischer.   

Abstract

Parkinson's disease (PD) is characterized by the progressive loss of substantia nigra dopaminergic neurons and the presence of cytoplasmic inclusions named Lewy bodies. Two missense mutations of the alpha-synuclein (alpha-syn; A30P and A53T) have been described in several families with an autosomal dominant form of PD. alpha-Syn also constitutes one of the main components of Lewy bodies in sporadic cases of PD. To develop an animal model of PD, lentiviral vectors expressing different human or rat forms of alpha-syn were injected into the substantia nigra of rats. In contrast to transgenic mice models, a selective loss of nigral dopaminergic neurons associated with a dopaminergic denervation of the striatum was observed in animals expressing either wild-type or mutant forms of human alpha-syn. This neuronal degeneration correlates with the appearance of abundant alpha-syn-positive inclusions and extensive neuritic pathology detected with both alpha-syn and silver staining. Lentiviral-mediated expression of wild-type or mutated forms of human alpha-syn recapitulates the essential neuropathological features of PD. Rat alpha-syn similarly leads to protein aggregation but without cell loss, suggesting that inclusions are not the primary cause of cell degeneration in PD. Viral-mediated genetic models may contribute to elucidate the mechanism of alpha-syn-induced cell death and allow the screening of candidate therapeutic molecules.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12122208      PMCID: PMC125054          DOI: 10.1073/pnas.152339799

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

Review 1.  Pathology and biology of the Lewy body.

Authors:  M S Pollanen; D W Dickson; C Bergeron
Journal:  J Neuropathol Exp Neurol       Date:  1993-05       Impact factor: 3.685

2.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.

Authors:  R Krüger; W Kuhn; T Müller; D Woitalla; M Graeber; S Kösel; H Przuntek; J T Epplen; L Schöls; O Riess
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

3.  Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector.

Authors:  U Blömer; L Naldini; T Kafri; D Trono; I M Verma; F H Gage
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

4.  Alpha-synuclein in Lewy bodies.

Authors:  M G Spillantini; M L Schmidt; V M Lee; J Q Trojanowski; R Jakes; M Goedert
Journal:  Nature       Date:  1997-08-28       Impact factor: 49.962

5.  alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies.

Authors:  M G Spillantini; R A Crowther; R Jakes; M Hasegawa; M Goedert
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

6.  Bcl-xL protects adult septal cholinergic neurons from axotomized cell death.

Authors:  U Blömer; T Kafri; L Randolph-Moore; I M Verma; F H Gage
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

7.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors:  M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

8.  The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system.

Authors:  A Iwai; E Masliah; M Yoshimoto; N Ge; L Flanagan; H A de Silva; A Kittel; T Saitoh
Journal:  Neuron       Date:  1995-02       Impact factor: 17.173

9.  NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease.

Authors:  K Wakabayashi; K Matsumoto; K Takayama; M Yoshimoto; H Takahashi
Journal:  Neurosci Lett       Date:  1997-12-12       Impact factor: 3.046

10.  The alpha-synuclein Ala53Thr mutation is not a common cause of familial Parkinson's disease: a study of 230 European cases. European Consortium on Genetic Susceptibility in Parkinson's Disease.

Authors:  J Vaughan; A Durr; J Tassin; B Bereznai; T Gasser; V Bonifati; G De Michele; E Fabrizio; G Volpe; O Bandmann; W G Johnson; L I Golbe; M Breteler; G Meco; Y Agid; A Brice; C D Marsden; N W Wood
Journal:  Ann Neurol       Date:  1998-08       Impact factor: 10.422

View more
  163 in total

Review 1.  Parkinson's disease: a rethink of rodent models.

Authors:  Heather L Melrose; Sarah J Lincoln; Glenn M Tyndall; Matthew J Farrer
Journal:  Exp Brain Res       Date:  2006-04-26       Impact factor: 1.972

Review 2.  Etiology of Parkinson's disease: Genetics and environment revisited.

Authors:  Kathy Steece-Collier; Eleonora Maries; Jeffrey H Kordower
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-21       Impact factor: 11.205

3.  Attack on amyloid.

Authors:  Philipp J Kahle; Bart De Strooper
Journal:  EMBO Rep       Date:  2003-07-25       Impact factor: 8.807

Review 4.  Lentiviral vector-mediated gene transfer and RNA silencing technology in neuronal dysfunctions.

Authors:  Jean-Luc Dreyer
Journal:  Mol Biotechnol       Date:  2011-02       Impact factor: 2.695

Review 5.  Drug targets from genetics: α-synuclein.

Authors:  Karin M Danzer; Pamela J McLean
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

6.  Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.

Authors:  Christophe Lo Bianco; Bernard L Schneider; Matthias Bauer; Ali Sajadi; Alexis Brice; Takeshi Iwatsubo; Patrick Aebischer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-02       Impact factor: 11.205

7.  Corynoxine, a natural autophagy enhancer, promotes the clearance of alpha-synuclein via Akt/mTOR pathway.

Authors:  Lei-Lei Chen; Ju-Xian Song; Jia-Hong Lu; Zhen-Wei Yuan; Liang-Feng Liu; Siva Sundara Kumar Durairajan; Min Li
Journal:  J Neuroimmune Pharmacol       Date:  2014-02-13       Impact factor: 4.147

Review 8.  α-Synuclein nonhuman primate models of Parkinson's disease.

Authors:  David J Marmion; Jeffrey H Kordower
Journal:  J Neural Transm (Vienna)       Date:  2017-04-22       Impact factor: 3.575

Review 9.  Molecular mechanisms of alpha-synuclein neurodegeneration.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  Biochim Biophys Acta       Date:  2008-10-09

10.  Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy.

Authors:  Chee Yeun Chung; James B Koprich; Hasan Siddiqi; Ole Isacson
Journal:  J Neurosci       Date:  2009-03-18       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.